A Study of the Safety and Tolerability of MEDI-570 (Experimental Drug) in Systemic Lupus Erythematosus

Inclusion Criteria:

• Meet or have met at least 4 of the 11 revised American College of Rheumatology (ACR) classification criteria for SLE
• Score ≥ 6 points on the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) at screening
• Ability to complete the study period, including follow-up period through Day 169
• Willingness to forego other forms of experimental treatment during the study.

Exclusion Criteria:

• History of cancer except basal cell carcinoma treated with apparent success with curative therapy ≥ 1 year before randomization into the study
• Evidence of active or latent tuberculosis (TB)
• History of primary immunodeficiency
• Evidence of infection at any time with hepatitis B or C virus or human immunodeficiency virus HIV-1 or HIV-2, or active infection with hepatitis A, as determined by results of testing at screening
• History of sepsis or serious, recurrent, chronic infection, current signs and symptoms of clinically significant chronic infection, or recent (within 6 months before baseline visit) serious infection
• Any history or evidence of opportunistic infection within 6 months of screening including severe cytomegalovirus (CMV) or herpetic infections (such as disseminated herpes, herpes encephalitis, ophthalmic herpes)
• Receipt of cyclophosphamide (IV or oral) within 6 months of screening
• Have any absolute contraindications to skin punch biopsies, for example, a history of coagulation disorders